Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Status:
Completed
Trial end date:
2017-05-22
Target enrollment:
Participant gender:
Summary
The primary objectives of this Phase 1b/2 study were as follows:
- Phase 1b (Bolus and Infusion): To evaluate the safety and tolerability of carfilzomib in
patients with relapsed solid tumors and in patients with relapsed and/or refractory
multiple myeloma and in patients with refractory lymphoma.
- Phase 2 (Bolus): To evaluate the overall response rate (ORR) after 4 cycles of
carfilzomib in patients with relapsed solid tumors.